What is P21?
P21 is a research-market label that needs sequence confirmation. The selected paper studied the CNTF-derived candidate P021; it is presented as related research rather than proof that every product labeled P21 has that identity.
Biological role or research focus
CNTF-derived candidate and P021 research context.
P021 evidence is related candidate evidence until the P21 preparation’s identity is verified. Animal cognition measures also do not establish a human benefit.
Role reference: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
Names you may encounter
Peptide 21
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Ambiguous research label; exact sequence requires confirmation
- Research focus
- CNTF-derived candidate and P021 research context
- Featured evidence
- Related candidate · Animal study
- Source check
- October 4, 2026
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
Quick answers
- Is P21 FDA approved?
- No. No FDA-approved drug contains P21. Source ↗
- Is P21 safe?
- Unapproved research compound of uncertain identity with no published human safety studies; its risks in people are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is P21 banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| P021 in aged rats (2014) | Aged Fischer rats, approximately 22–24 months old. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Related candidate · Animal study · 2014
P021 in aged rats
What did this publication test, and what did it find?
- Population / model
- Aged Fischer rats, approximately 22–24 months old.
- Study design
- Oral P021 intervention with learning, memory, and brain-marker measurements.
- Main finding
- The report described improved learning and memory measures with changes in BDNF, neurogenesis, and synaptic markers in aged rats.
- Limits & context
- P021 evidence is related candidate evidence until the P21 preparation’s identity is verified. Animal cognition measures also do not establish a human benefit.
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming P21 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 0 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The P21 market label does not establish a sequence. Searches also return unrelated p21 biology. No further records are assigned until candidate identity is verified; the existing P021 note remains related-candidate evidence.
Repeat this PubMed search ↗Risks & interactions
Unapproved research compound of uncertain identity with no published human safety studies; its risks in people are unknown.
No published human studies were found. Related evidence is an aged-rat study of P021, and products sold as P21 may not match that compound, so no compound-specific safety profile exists.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Rescue of cognitive aging by a neurogenic compound in rats (2014) ↗
Safety & what remains unknown
Unresolved sequence identity prevents assigning a unique structure or a candidate-specific safety profile.
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
Evidence boundaries
P021 evidence is related candidate evidence until the P21 preparation’s identity is verified. Animal cognition measures also do not establish a human benefit.
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
P21 also appears in unrelated biological terminology. A catalog name alone is insufficient to establish a CNTF-derived sequence or match the published P021 compound.
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The P021 study investigated neurotrophic, neurogenesis, and synaptic measures. These candidate-specific observations should not be assigned to an unidentified peptide.
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
Questions worth asking
- Is every P21 product confirmed to be the paper’s P021?
- What material, population, and route were actually studied?
- P021 evidence is related candidate evidence until the P21 preparation’s identity is verified. Animal cognition measures also do not establish a human benefit.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Is every P21 product confirmed to be the paper’s P021?
No. A sequence and modification specification are needed. This page keeps the published P021 candidate and an unverified P21 label distinct.
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. · 2014 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
